Other Deals Are Up 1271% in 2026 — Here's the Data

Other deal activity surged 1271% period over period in 2026 — from 7 deals recorded between August 27, 2025 and February 27, 2026, to 96 deals between February 27, 2026 and August 27, 2026. This isn't noise. Big Pharma is aggressively acquiring and licensing assets that don't fit neatly into traditional modality buckets — platform technologies, diagnostic-therapeutic hybrids, radiopharmaceuticals, cell therapies with novel engineering, and AI-native drug discovery engines — and the deal velocity tells you that conventional pipeline strategies have hit a wall.

The Data — Other Deal Activity, Period over Period

A 1271% increase demands scrutiny. Seven deals in six months is a rounding error — a category barely worth tracking. Ninety-six deals in the subsequent six months is a market. Something fundamental changed between Q4 2025 and Q2 2026, and the data strongly suggests it wasn't a single catalyst but a convergence of forces that turned "other" from a catch-all into a strategic priority. Check how this compares to established modalities in our Deal Benchmarks tracker.

What's Driving the Trend

Pipeline exhaustion in traditional modalities is the primary accelerant. The antibody space is saturated — over 200 PD-(L)1 combinations are in clinical development globally, and GLP-1 agonist competition now includes 15+ late-stage programs. Big Pharma BD teams are under pressure to find differentiated assets, and the definition of "differentiated" increasingly means modalities that don't have a clean category label. Radiopharmaceutical conjugates, gene editing platforms beyond CRISPR-Cas9, engineered exosomes, synthetic biology chassis — these are the assets generating competitive term sheets in 2026.

Regulatory tailwinds are making unconventional assets more financeable. The FDA's RMAT designation pathway matured considerably in late 2025, and the agency's Project Optimus-driven dosing flexibility has made novel therapeutic modalities less risky from a development standpoint. When regulatory risk drops, deal premiums rise. That's exactly what we're seeing: licensors of other-category assets are commanding upfronts and total deal values that would have been reserved for late-stage small molecules three years ago.

Capital structure dynamics are also at play. Biotech balance sheets improved meaningfully in H1 2026 after the IPO window cracked open in Q1. Companies that would have accepted acqui-hire terms in 2024 are now running competitive BD processes. The result: more deals getting done, at higher valuations, across a wider spectrum of modalities. The 1271% jump in other licensing 2026 is partly a reclassification story — assets that would have been force-fit into "biologic" or "small molecule" categories in prior years are now being tracked in their own right — but the absolute deal count of 96 is too large to dismiss as mere taxonomy.

Notable Deals

The CSPC Pharmaceutical–AstraZeneca deal is the headline. A $1.2B upfront and $18.5B total deal value is top-decile for any modality in any year. AstraZeneca paid this for Chinese-origin assets that six quarters ago would have struggled to find a Western partner amid geopolitical licensing headwinds. The fact that AZ came back for a second CSPC deal within three days ($1.77B TDV on July 15) signals deep strategic conviction, not opportunistic bolt-on behavior. Run these numbers against historical comparables on Solidus — the upfront-to-TDV ratio of ~6.5% sits below the typical 8–12% range for oncology deals, suggesting AZ structured this with heavy milestone loading. That's a licensor trade-off worth studying.

Novo Nordisk's $2.4B TDV deal with Omeros marks the Danish giant's continued push beyond metabolic disease. Omeros's complement-targeted pipeline in renal disorders gave Novo a differentiated entry point that doesn't overlap with its GLP-1 franchise. BridgeBio's $105M upfront from Novartis validates what the cardiometabolic market already knew — genetic medicine platforms outside of traditional gene therapy vectors command premium economics when paired with clinical proof-of-concept. The Amgen–BeiGene deal, while lacking disclosed financial terms, extends a partnership pattern we've seen accelerate in 2026: US-China bilateral deals re-emerging after the chill of 2023–2024.

What This Means for BD Teams Right Now

If you're a licensor with an unconventional asset, this is a seller's market — but only if you have clinical data. The 96-deal surge in other deal trends 2026 has not eliminated diligence rigor; it has compressed timelines. Pharma BD teams are running parallel evaluations on 3–5 competing assets simultaneously, which means your process window is shorter. Get your data room audit-ready now. Competitive tension is real but perishable.

If you're a buyer, the arbitrage on early-stage "other" modality assets is closing fast. Six months ago you could option a novel platform for $5–15M upfront with generous milestone triggers. The CSPC–AZ deal repriced the market. Expect upfront demands to increase 30–50% over H2 2025 levels, particularly for assets with any clinical validation in oncology or immunology. The smart move: lock in option-to-license structures now, before Q4 2026 JPM conversations push expectations even higher.

Deal structures are evolving. We're seeing a marked increase in equity components (co-investment or equity stakes as part of upfront consideration), territorial carve-outs that let licensors retain rights in China or Asia-Pacific, and milestone schedules tied to regulatory submissions rather than approvals — reflecting both parties' desire to accelerate value recognition. If your standard term sheet hasn't been updated since 2024, you're negotiating with outdated architecture. Benchmark your terms against current Deal Benchmarks data before your next LOI goes out.

Benchmark your deal against current market rates using the Ambrosia calculator. The other modality surge has fundamentally shifted what "market" means for non-traditional assets — make sure your valuation framework reflects 2026 reality, not 2024 precedent.